United States - English - NLM (National Library of Medicine)

7t pharma llc - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 0.5 mg - zingo is indicated for use on intact skin to provide topical local analgesia prior to venipuncture or peripheral intravenous cannulation, in children 3–18 years of age. zingo is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults. zingo is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. zingo was not formally evaluated for effects on reproduction. significant systemic exposure to lidocaine is not expected under recommended conditions of use of zingo as lidocaine levels were below the limit of detection in human studies. lidocaine has been previously tested for reproductive toxicity in animal studies, however. the following ratios are based on the assumption that the applied dose is completely absorbed through the skin. teratogenic effects pregnancy category b. lidocaine was not teratogenic in rats given subcutaneous doses up to 60 mg/kg [360 mg/m 2 or 1200-fold the single dermal administration (sda) of 0

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recomm

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - lidocaine hydrochloride monohydrate - solution for injection - lidocaine hydrochloride monohydrate 10 mg/ml - lidocaine - local and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 426.4 mg (equivalent: lidocaine hydrochloride, qty 400 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 21.32 mg (equivalent: lidocaine hydrochloride, qty 20 mg) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 42.64 mg (equivalent: lidocaine hydrochloride, qty 40 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 53.3 mg (equivalent: lidocaine hydrochloride, qty 50 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 213.2 mg (equivalent: lidocaine hydrochloride, qty 200 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 106.6 mg (equivalent: lidocaine hydrochloride, qty 100 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride - lidocaine noridem solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia, peripheral nerve block, epidural block, subarachnoid block.

Ireland - English - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - lidocaine hydrochloride monohydrate - solution for injection - 1 percent - lidocaine